BioCentury | Aug 7, 2020
Management Tracks

Greene, an architect of Alnylam, looks to the next chapter

...amyloidosis (see “First RNAi Drug Approval” ). Prior to Alnylam, Greene spent two years at Millennium Pharmaceuticals Inc....
...granting Johnson & Johnson (NYSE:JNJ) ex-U.S. rights to the multiple myeloma drug. His time at Millennium...
BioCentury | Jul 1, 2020
Emerging Company Profile

With potential for re-dosing, Carmine’s gene therapy tech attracts Takeda as partner

...also a co-founder. Lodish has helped found several biotechs, including Genzyme Inc., Axys Pharmaceuticals Inc., Millennium Pharmaceuticals Inc....
BioCentury | Jan 29, 2020
Company News

Decibel narrows discovery focus to inner ear regeneration, taps Reid as CEO

...before that CBO at Millennium Pharmaceuticals Inc., which Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) acquired. At Infinity and Millennium...
BioCentury | Jan 1, 2020
Company News

Fewer FDA approvals in 2019, but a basket of firsts

...by medicine since the start of the century (see “It’s Been a Hell of a Millennium...
BioCentury | Dec 21, 2019
Product Development

It’s been a hell of a millennium -- and it’s just getting started

...few diseases where the outlook for patients is completely different from the start of the millennium...
BioCentury | Sep 6, 2019
Regulation

Lackluster U.S. biosimilars market sparks radical recommendations

...regulatory affairs at Baxalta Inc. and has led biologics regulatory teams at Novartis Vaccines and Millennium Pharmaceuticals Inc....
BioCentury | Feb 11, 2019
Company News

Agios' Schenkein joins GV

...Agios, will co-lead the firm’s life science investment team. A veteran of Genentech Inc. and Millennium Pharmaceuticals Inc....
...the company’s BioOncology portfolio. Prior to joining Genentech, he was SVP of clinical research at Millennium...
...clinical development and worldwide approval of Velcade bortezomib. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) acquired Millennium...
BioCentury | Jan 11, 2019
Product R&D

PureTech turns inward

...after serving as CSO at Moderna Inc. Prior to that he was CSO at the Millennium Pharmaceuticals Inc....
BioCentury | Sep 11, 2018
Company News

Management tracks: Cheng joins Akero, bluebird COO leaving

...leave the company on Jan. 4, 2019. A veteran of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and Millennium Pharmaceuticals Inc....
BioCentury | Aug 24, 2018
Finance

Navigating the Hot Topics landscape

...new medicines to patients. NewsMakers Luncheon Panel Friday, Sept. 7, 2018 12:15 - 1:15 PM Millennium...
Items per page:
1 - 10 of 1873
BioCentury | Aug 7, 2020
Management Tracks

Greene, an architect of Alnylam, looks to the next chapter

...amyloidosis (see “First RNAi Drug Approval” ). Prior to Alnylam, Greene spent two years at Millennium Pharmaceuticals Inc....
...granting Johnson & Johnson (NYSE:JNJ) ex-U.S. rights to the multiple myeloma drug. His time at Millennium...
BioCentury | Jul 1, 2020
Emerging Company Profile

With potential for re-dosing, Carmine’s gene therapy tech attracts Takeda as partner

...also a co-founder. Lodish has helped found several biotechs, including Genzyme Inc., Axys Pharmaceuticals Inc., Millennium Pharmaceuticals Inc....
BioCentury | Jan 29, 2020
Company News

Decibel narrows discovery focus to inner ear regeneration, taps Reid as CEO

...before that CBO at Millennium Pharmaceuticals Inc., which Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) acquired. At Infinity and Millennium...
BioCentury | Jan 1, 2020
Company News

Fewer FDA approvals in 2019, but a basket of firsts

...by medicine since the start of the century (see “It’s Been a Hell of a Millennium...
BioCentury | Dec 21, 2019
Product Development

It’s been a hell of a millennium -- and it’s just getting started

...few diseases where the outlook for patients is completely different from the start of the millennium...
BioCentury | Sep 6, 2019
Regulation

Lackluster U.S. biosimilars market sparks radical recommendations

...regulatory affairs at Baxalta Inc. and has led biologics regulatory teams at Novartis Vaccines and Millennium Pharmaceuticals Inc....
BioCentury | Feb 11, 2019
Company News

Agios' Schenkein joins GV

...Agios, will co-lead the firm’s life science investment team. A veteran of Genentech Inc. and Millennium Pharmaceuticals Inc....
...the company’s BioOncology portfolio. Prior to joining Genentech, he was SVP of clinical research at Millennium...
...clinical development and worldwide approval of Velcade bortezomib. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) acquired Millennium...
BioCentury | Jan 11, 2019
Product R&D

PureTech turns inward

...after serving as CSO at Moderna Inc. Prior to that he was CSO at the Millennium Pharmaceuticals Inc....
BioCentury | Sep 11, 2018
Company News

Management tracks: Cheng joins Akero, bluebird COO leaving

...leave the company on Jan. 4, 2019. A veteran of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and Millennium Pharmaceuticals Inc....
BioCentury | Aug 24, 2018
Finance

Navigating the Hot Topics landscape

...new medicines to patients. NewsMakers Luncheon Panel Friday, Sept. 7, 2018 12:15 - 1:15 PM Millennium...
Items per page:
1 - 10 of 1873